- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14:46 | AbbVie lands FDA approval for next-generation Parkinson's drug, Juvmo | ||
| 11:46 | Novo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa | ||
| 11:46 | Daiichi Sankyo, MSD withdraw cancer drug application | ||
| 08:46 | Mirum and Incyte's Atebrioz approved for FOP in US | ||
| Fr | Aptar Pharma and Macquarie University partner on drug delivery project | ||
| Fr | FDA commissioner nominee affirms MMR vaccine safety despite Trump's claims | ||
| Fr | Roche and Earendil forge $1.5bn bispecific discovery deal | ||
| Fr | Amberstone and Henlius agree to develop solid-tumour T-cell engagers | ||
| Fr | FDA approves Lilly's Onswik for type 2 diabetes in adults | ||
| Do | Eli Lilly outlays $3.35bn for secretive drug discovery pact with China's InnoCare | ||
| Do | Australia starts investigation into OpenAI Medicare breach | ||
| Do | Enveda nabs $311m to progress nature-derived drug pipeline | ||
| Do | Genialis and Inventia to enhance pancreatic cancer treatment testing | ||
| Do | Basecamp Research secures $140m for AI-driven therapies | ||
| Mi | European big pharma unites amid 'ringing alarm bells' of continent's dominance | ||
| Mi | Boehringer and Envisagenics to develop precision cancer therapies in $1bn deal | ||
| Mi | BoomRay and Novartis Pharma sign $900m deal for radioligand therapy | ||
| Mi | Boehringer and Envisagenics to develop precision cancer therapies | ||
| Di | Novo targets blockbuster-heavy 2030 but share slump signals unease | ||
| Di | Made Scientific acquires cell therapy facility in Pennsylvania, US | ||
| Di | EC approves Menarini and NewAmsterdam's obicetrapib therapies | ||
| 21.09. | Beijing unveils blueprint for biomedical dominance by 2030 | ||
| 21.09. | Telix to acquire ITM in deal worth up to $2.35bn | ||
| 21.09. | Sandoz and mAbxience agree on emicizumab biosimilar partnership | ||
| 18.09. | FDA approves first gene therapy for Sanfilippo syndrome type A |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.